Medicure posts investor presentation outlining US growth strategy for Zypitamag, Aggrastat, Marley Drug pharmacy unit

Reuters2026/08/06 15:43

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Medicure outlined a US-focused plan to expand revenue from ZYPITAMAG, AGGRASTAT, Marley Drug, while funding R&D and acquisitions from profit.
Marley Drug revenue totaled CAD 20.3 million in 2025, up 88%, supported by expanded dispensing and broader e-commerce pharmacy sales.
ZYPITAMAG net revenue reached CAD 6.5 million in 2025, up 5%, targeting the roughly USD 4 billion statin market.
AGGRASTAT net revenue was CAD 5.7 million in 2025, up 29%, positioning the product as a leading IV antiplatelet used in over 1,000 hospitals.
MC-1 Phase 3 trial in PNPO deficiency targets 10-15 patients; approval could yield a priority review voucher valued at about USD 150-200 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicure Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Medicure posts investor presentation outlining US growth strategy for Zypitamag, Aggrastat, Marley Drug pharmacy unit

You may also like

Crypto prices